TransMedics, Inc. Appointed Jeffrey E. Young as Chief Financial Officer

TransMedics, Inc. Appointed Jeffrey E. Young as Chief Financial Officer

November 8, 2013

ANDOVER, Mass., Nov. 8, 2013 /PRNewswire/ -- TransMedics, Inc., an emerging medical technology company dedicated to extending the life-saving benefits of organ transplantation to patients suffering from end-stage organ failure, announced today that Jeffrey E. Young was appointed to the position of Chief Financial Officer and Treasurer, effective August 2013. Mr. Young, is responsible for the Company's finance, accounting, and treasury functions and reports directly to Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics, Inc.

Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results

Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results

November 7, 2013

Successfully Completed Initial Public Offering and Advanced IDH2 Cancer Metabolism Program into Clinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2013.

Black Duck Maintains Rapid Pace With Record-Breaking Third Quarter

Black Duck Maintains Rapid Pace With Record-Breaking Third Quarter

November 7, 2013

New Customer Acquisition, Growth in EMEA and Asia-Pacific, and Expansion in Financial Services, Retail, Online Services, Automotive and Health Care Propel Growth

Tetraphase Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Tetraphase Pharmaceuticals Announces Pricing of Public Offering of Common Stock

November 7, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, less underwriting discounts and commissions. The size of the offering was upsized from 3.3 million shares to 4.5 million shares, raising aggregate gross proceeds of $45 million. Tetraphase has granted the underwriters a 30-day option to purchase 675,000 additional shares of common stock on the same terms and conditions.

BG Medicine Reports 2013 Third Quarter Financial Results

BG Medicine Reports 2013 Third Quarter Financial Results

November 6, 2013

Capital Health Accountable Care Organization LLC Adopts BGM Galectin-3® Test

Network of Laboratories in U.S. Offering BGM Galectin-3Test Expanded

Full-Year 2013 Product Revenue and Cash Burn Guidance Confirmed

WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, today reported financial results for the third quarter of 2013.

SilverStaff Clinical Laboratories to Offer BGM Galectin-3(R) Test

SilverStaff Clinical Laboratories to Offer BGM Galectin-3(R) Test

November 6, 2013

WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test and SilverStaff Clinical Laboratories, Inc. today announced that SilverStaff will be offering galectin-3 testing services to its laboratory customers and physicians.

Mascoma Adds Two Industry Experts to Board of Directors

Mascoma Adds Two Industry Experts to Board of Directors

November 6, 2013

LEBANON, N.H., Nov 06, 2013 (BUSINESS WIRE) -- Mascoma Corporation, a bioconversion company, announced today that they have appointed two new members to its Board of Directors, Steve Percy, former Chairman and CEO of BP America and Dan Nelson, former Vice President of ExxonMobil.

EcoSense Lighting Closes $15M Financing Round Amidst Rapid Growth

EcoSense Lighting Closes $15M Financing Round Amidst Rapid Growth

November 5, 2013

New York, NY, November 5, 2013 - EcoSense Lighting®, a fast-growing manufacturer of highperformance white LED luminaires, announced it has closed a $15 million funding round with a significant investment from Flagship Ventures, as well as a follow-on investment from Bain Capital Ventures. This investment will be used to accelerate new product introductions, enhance R&D capabilities and ensure our operations infrastructure exceeds the rising demands of our customers.

Avedro Announces CE Mark Clearance for its KXL II ™ Advanced Cross-linking System

Avedro Announces CE Mark Clearance for its KXL II ™ Advanced Cross-linking System

November 5, 2013

Offering the Potential for a Non-surgical Alternative to Lasik and for Improving Cataract Surgery Outcomes

WALTHAM, Mass.--(EON: Enhanced Online News)--Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces CE Mark clearance for its KXL II System. The KXL II System has the potential for non-surgical correction of myopia, as well as improving cataract surgery outcomes, with a procedure called PiXL™ (Photorefractive Intrastromal Cross-linking).

Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System

Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System

November 4, 2013

CAMBRIDGE, Mass., Nov. 4, 2013 -- /PRNewswire/ -- Seventh Sense Biosystems, Inc., the leading developer of painless blood collection and diagnostic platforms, today announced it has obtained CE Mark approval for its Touch Activated Phlebotomy (TAP™) platform for blood collection and testing.